drugset / Trial / NCT00724048
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.
Timeline
- Start
- 2008-10-24
- Primary completion
- 2010-07-26
- Completion
- 2010-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pridopidine | Small molecule | 10 mg | Oral |
| Subject | Pridopidine | Small molecule | 22.5 mg | Oral |
| Subject | Pridopidine | Small molecule | 45 mg | Oral |